DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s TSLP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036.” The report provides a comprehensive understanding of TSLP inhibitors, including epidemiology, market trends, treatment landscape, competitive intelligence, emerging therapies, and forecasted market dynamics across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the TSLP Inhibitors Market

• The TSLP Inhibitors market across the 7MM is expected to exhibit substantial growth during the forecast period from 2026 to 2036, driven by expanding label opportunities and increasing adoption across multiple inflammatory diseases.

• The TSLP Inhibitors market size in the 7MM was approximately USD 10 billion in 2022 and is projected to reach nearly USD 16 billion by 2036.

• The United States accounted for the largest share of the TSLP Inhibitors market in 2025, generating approximately USD 4.1 billion in revenue.

• According to DelveInsight’s assessment, approximately 56 million diagnosed prevalent cases of asthma were reported across the 7MM in 2025, representing a major target population for TSLP inhibitors.

• The 7MM accounted for approximately 31 million diagnosed prevalent cases of Chronic Obstructive Pulmonary Disease (COPD) in 2025, with the patient population expected to increase during the forecast period.

• In 2025, the United States reported approximately 17 million diagnosed prevalent COPD cases, highlighting a significant commercial opportunity for TSLP-targeted therapies.

• Among EU4 and the United Kingdom, the UK accounted for the highest number of diagnosed prevalent asthma cases in 2025, with approximately 8.5 million cases.

• Japan recorded approximately 9 million diagnosed prevalent cases of atopic dermatitis in 2025, representing a substantial patient pool for future TSLP-targeted treatment expansion.

• Leading companies operating in the TSLP inhibitor landscape include AstraZeneca, Amgen, Sanofi, Upstream Bio, Uniquity Bio, and others.

• Promising TSLP inhibitors in clinical development include Lunsekimig (SAR443765), Verekitug (UPB-101), Solrikitug, and additional next-generation biologics designed to enhance upstream inflammatory pathway modulation.

Keen to know more about the market? Request our sample page. https://www.delveinsight.com/sample-request/tslp-inhibitors-market-forecast

Key Factors Driving the TSLP Inhibitors Market

• Increasing Disease Burden of Respiratory and Allergic Disorders: The growing prevalence of asthma, COPD, atopic dermatitis, and chronic rhinosinusitis with nasal polyps is creating significant demand for novel therapeutic options capable of delivering broad and durable disease control.

• Growing Interest in Upstream Immune Modulation: TSLP acts as a master regulator of epithelial-driven inflammation. Targeting this upstream cytokine enables simultaneous suppression of multiple downstream inflammatory pathways, offering advantages over cytokine-specific biologics.

• Expanding Therapeutic Applications: The successful clinical performance of TEZSPIRE has encouraged broader exploration of TSLP inhibition across multiple inflammatory conditions, creating opportunities for significant label expansion and market penetration.

• Advancements in Precision Immunology: Improved understanding of disease biology and inflammatory pathways is supporting the development of next-generation TSLP inhibitors and dual-target biologics, enabling more personalized treatment approaches.

TSLP Inhibitors Competitive Landscape

The TSLP inhibitors market is currently led by TEZSPIRE (tezepelumab-ekko), the first and only approved TSLP-targeting therapy across the United States, Europe, the United Kingdom, and Japan. TEZSPIRE has established TSLP as a clinically validated upstream inflammatory target and has demonstrated broad efficacy across severe asthma populations regardless of biomarker status.

Several emerging therapies are expected to intensify competition within the market. Lunsekimig (SAR443765), being developed by Sanofi, is a dual TSLP/IL-13 monoclonal antibody designed to deliver broader suppression of epithelial-driven inflammation. Verekitug (UPB-101), developed by Upstream Bio, is advancing across airway inflammatory diseases with the potential for infrequent dosing schedules. Solrikitug, developed by Uniquity Bio, represents a next-generation anti-TSLP antibody designed with enhanced binding properties and superior in vitro potency.

These emerging therapies aim to improve disease control, reduce exacerbations, and provide differentiated treatment options for patients with inflammatory airway diseases.

Discover more about therapies set to grab major TSLP Inhibitors market share.

Recent Developments in the TSLP Inhibitors Market

• In October 2025, the US FDA approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance therapy for inadequately controlled chronic rhinosinusitis with nasal polyps in patients aged 12 years and older.

• In July 2024, AstraZeneca announced that the US FDA granted Breakthrough Therapy Designation (BTD) to tezepelumab for the treatment of patients with moderate-to-very severe COPD characterized by an eosinophilic phenotype.

• In September 2025, Sanofi advanced Lunsekimig (SAR443765) into Phase II/III development through the THESEUS and PERSEPHONE clinical trials evaluating patients with COPD.

• In September 2025, Upstream Bio reported positive Phase II VIBRANT study results demonstrating that Verekitug significantly reduced nasal polyp scores in patients with chronic rhinosinusitis with nasal polyps.

• In June 2025, data presented at the American Thoracic Society International Conference demonstrated that Solrikitug exhibited superior in vitro potency compared with tezepelumab, supporting its development as a next-generation anti-TSLP antibody.

What are TSLP Inhibitors?

Thymic Stromal Lymphopoietin (TSLP) inhibitors are biologic therapies that target TSLP, an epithelial-derived cytokine that plays a central role in initiating and amplifying inflammatory signaling across respiratory and allergic diseases. TSLP is released in response to environmental and inflammatory stimuli and functions upstream of multiple immune pathways, making it an attractive therapeutic target. By inhibiting TSLP, these therapies aim to suppress both innate and adaptive immune activation, reduce inflammatory amplification, and provide broader disease control across diverse inflammatory phenotypes.

Currently, TEZSPIRE is the only approved TSLP inhibitor; however, multiple next-generation therapies are advancing through clinical development and are expected to expand treatment options significantly over the coming decade.

TSLP Inhibitors Epidemiology Segmentation

The TSLP Inhibitors epidemiology section provides insights into historical and forecasted patient populations across the seven major markets. The report offers epidemiological analysis for the study period 2022–2036 segmented into:

• Total Cases in Selected Indications for TSLP Inhibitors

• Total Eligible Patient Pool for TSLP Inhibitors

• Total Treated Cases for TSLP Inhibitors

• Asthma Patient Population

• COPD Patient Population

• Atopic Dermatitis Patient Population

• Country-specific Patient Population

Scope of the TSLP Inhibitors Market Report

• Therapeutic Assessment: Current marketed and emerging TSLP inhibitors

• TSLP Inhibitors Market Dynamics: Key Market Forecast Assumptions and Market Outlook

• Key Companies: AstraZeneca, Amgen, Sanofi, Upstream Bio, Uniquity Bio, and others

• Key Therapies: TEZSPIRE (tezepelumab-ekko), Lunsekimig (SAR443765), Verekitug (UPB-101), Solrikitug, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL Views, Analyst Perspectives, Market Access and Reimbursement Assessment

To know more about companies working in the TSLP inhibitors treatment market, visit TSLP Inhibitors Clinical Trials and Therapeutic Assessment.

Table of Contents

1. TSLP Inhibitors Market Report Introduction

2. Executive Summary for TSLP Inhibitors

3. TSLP Inhibitors Background and Overview

4. TSLP Inhibitors Epidemiology and Target Population

5. Country-Specific Patient Population Analysis

6. Current Treatment Landscape

7. Marketed Therapies

8. Emerging Therapies

9. Market Outlook

10. TSLP Inhibitors Market Analysis (2022–2036)

11. Market Size by Therapy

12. Market Access and Reimbursement

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions that enhance business performance. Through its subscription-based platform PharmDelve, DelveInsight provides seamless access to healthcare and pharmaceutical market research reports worldwide.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services